Should I buy or sell BiomX stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BiomX in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PHGE shares. View PHGE analyst ratings or view top-rated stocks .

What is BiomX's stock price target for 2024?

1 brokerages have issued 1-year price objectives for BiomX's stock. Their PHGE share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 2,232.6% from the stock's current price. View analysts price targets for PHGE or view top-rated stocks among Wall Street analysts .

How have PHGE shares performed in 2024?

BiomX's stock was trading at $0.28 on January 1st, 2024. Since then, PHGE stock has increased by 7.2% and is now trading at $0.3001. View the best growth stocks for 2024 here .

How were BiomX's earnings last quarter?

BiomX Inc. (NYSEMKT:PHGE) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.02.

What other stocks do shareholders of BiomX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiomX investors own include Abiomed (ABMD) , Catalent (CTLT) , Hologic (HOLX) , Merck & Co., Inc. (MRK) , Net Element (NETE) , Novavax (NVAX) , Quanterix (QTRX) , ARCA biopharma (ABIO) , AbbVie (ABBV) and AudioEye (AEYE) .

How do I buy shares of BiomX?

Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEMKT:PHGE

BiomX (PHGE) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PHGE Stock Alerts

$0.27

-0.03 (-9.23%)

(As of 04/16/2024 ET)

Compare

Today's Range: $0.27
▼
$0.30
50-Day Range: $0.21
▼
$0.68
52-Week Range: N/A

Volume: 186,938 shs
Average Volume: 68,601 shs
Market Capitalization: $15.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Stock Analysis Analyst Forecasts Chart Earnings Financials Headlines Insider Trades Ownership SEC Filings

Get BiomX alerts:

BiomX MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,232.6% Upside
$7.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.44) to ($0.36) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.12 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
BiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
BiomX has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for PHGE.

0.0

Dividend Strength

Dividend Yield
BiomX does not currently pay a dividend.
Dividend Growth
BiomX does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PHGE.

0.0

News and Social Media Coverage

Search Interest
Only 7 people have searched for PHGE on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added BiomX to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BiomX insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.21% of the stock of BiomX is held by insiders.
Percentage Held by Institutions
40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for BiomX are expected to grow in the coming year, from ($0.44) to ($0.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BiomX is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BiomX is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BiomX has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

About BiomX Stock (NYSEMKT:PHGE)

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

PHGE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PHGE Stock News Headlines

April 6, 2024 | uk.investing.com

BiomX receives going concern note from auditors

April 4, 2024 | globenewswire.com

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

April 16, 2024 | Crypto Swap Profits (Ad)

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

April 3, 2024 | msn.com

U.S. Futures Dip in Pre-Market, May WTI and June Brent Crude Prices Edge Higher

April 3, 2024 | globenewswire.com

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 27, 2024 | globenewswire.com

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

March 18, 2024 | globenewswire.com

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

March 7, 2024 | markets.businessinsider.com

BiomX Buy Rating Justified by Merger Synergy, Enhanced Financial Stability, and Promising Clinical Trials

April 16, 2024 | Crypto Swap Profits (Ad)

Claim Your Complimentary Bitcoin Reward

March 7, 2024 | markets.businessinsider.com

BiomX Acquisition and Clinical Trial Successes Prompt Buy Rating by Analyst Michael Higgins

March 7, 2024 | prnewswire.com

Shareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage Therapeutics

March 6, 2024 | msn.com

Why BiomX Stock Is Surging Today

March 6, 2024 | investorplace.com

Why Is BiomX (PHGE) Stock Up 147% Today?

March 6, 2024 | globenewswire.com

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

January 29, 2024 | msn.com

NanoViricides reports positive safety results for COVID drug candidate

November 14, 2023 | msn.com

BiomX GAAP EPS of -$0.13 misses by $0.03

November 14, 2023 | finance.yahoo.com

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

October 26, 2023 | msn.com

Mustang Bio stock jumps 10% on FDA acceptance of new drug application

August 9, 2023 | msn.com

HC Wainwright & Co. Reiterates BiomX (PHGE) Buy Recommendation

August 9, 2023 | msn.com

BiomX GAAP EPS of -$0.12 beats by $0.02

July 19, 2023 | uk.finance.yahoo.com

PHGE - BiomX Inc.

June 2, 2023 | finance.yahoo.com

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of BiomX Inc. (PHGE.WS)

May 31, 2023 | finance.yahoo.com

BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC)

May 16, 2023 | msn.com

HC Wainwright & Co. Maintains BiomX (PHGE) Buy Recommendation

May 12, 2023 | finance.yahoo.com

BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors

May 12, 2023 | msn.com

Why Is BiomX (PHGE) Stock Up 10% Today?

May 8, 2023 | finance.yahoo.com

BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023

See More Headlines

Receive PHGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2023
Today: 4/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEMKT
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NYSEMKT:PHGE
CUSIP: N/A
CIK: 1739174
Web: www.biomx.com
Phone: 972 7 23942377
Fax: N/A
Employees: 54
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +2,232.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,320,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -127.82%
Return on Assets: -56.50%

Debt

Debt-to-Equity Ratio: 0.51
Current Ratio: 2.84
Quick Ratio: 2.84

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.70 per share
Price / Book: 0.43

Miscellaneous

Outstanding Shares: 55,220,000
Free Float: 44,044,000
Market Cap: $16.57 million
Optionable: Not Optionable
Beta: 1.35

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Jonathan Eitan Solomon MBA (Age 47)
CEO & Director
Comp: $528.57k
Ms. Marina Wolfson CPA (Age 40)
CFO & Secretary
Comp: $279.42k
Dr. Merav Bassan Ph.D. (Age 58)
Chief Development Officer
Comp: $356.59k
Prof. Rotem Sorek Ph.D.
Scientific Founder
Dr. Eran Elinav M.D.
Ph.D., Scientific Founder
Dr. Timothy K. Lu M.D. (Age 43)
Ph.D., Scientific Founder
Ms. Inbal Benjamini-Elran
C.H.R.O
Mr. Assaf Oron (Age 50)
Chief Business Officer
Comp: $352.04k

Key Competitors

View All Competitors

Insiders

Assaf Oron
Bought 3,192 shares on 5/22/2023
Total: $861.84 ($0.27/share)

View All Insider Transactions

PHGE Stock Analysis - Frequently Asked Questions

Should I buy or sell BiomX stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BiomX in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PHGE shares.
View PHGE analyst ratings or view top-rated stocks.
What is BiomX's stock price target for 2024?: 1 brokerages have issued 1-year price objectives for BiomX's stock. Their PHGE share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 2,232.6% from the stock's current price.
View analysts price targets for PHGE or view top-rated stocks among Wall Street analysts.
How have PHGE shares performed in 2024?: BiomX's stock was trading at $0.28 on January 1st, 2024. Since then, PHGE stock has increased by 7.2% and is now trading at $0.3001.
View the best growth stocks for 2024 here.
How were BiomX's earnings last quarter?: BiomX Inc. (NYSEMKT:PHGE) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.02.

What other stocks do shareholders of BiomX own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BiomX investors own include Abiomed (ABMD), Catalent (CTLT), Hologic (HOLX), Merck & Co., Inc. (MRK), Net Element (NETE), Novavax (NVAX), Quanterix (QTRX), ARCA biopharma (ABIO), AbbVie (ABBV) and AudioEye (AEYE).
How do I buy shares of BiomX?: Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEMKT:PHGE) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BiomX (PHGE) Stock Price, News & Analysis

BiomX MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About BiomX Stock (NYSEMKT:PHGE)

PHGE Stock Price History

PHGE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

PHGE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™